Shenzhen Immvira Completes $58 Million Funding for Oncolytic Virus Therapies
publication date: Jun 17, 2020
Immvira Group, a Shenzhen biotech developing oncolytic virus therapies, completed a $58 million Series B financing. In May, the company announced US approval to start a trial of its lead product, T3011, an intratumoral injection that encodes IL12 and anti-PD-1. Because the candidate is administered directly to the tumor, it is expected to avoid the side effects of immune-oncology therapies. The B round was led by Huagai Capital, with participation by Apricot Capital, Cowin Capital and the lead investor from a previous round, presumably Hillhouse. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.